BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18751706)

  • 1. Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer.
    Campone M; Blasinska-Morawiec M; Tekiela A; Koralewski P; Pouget JC; Douville I; Brandely M
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):937-43. PubMed ID: 18751706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer.
    Nolè F; Crivellari D; Mattioli R; Pinotti G; Foa P; Verri E; Fougeray R; Brandely M; Goldhirsch A
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):673-80. PubMed ID: 19184601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study.
    Serin D; Verrill M; Jones A; Delozier T; Coleman R; Kreuser ED; Mross K; Longerey B; Brandely M
    Br J Cancer; 2005 Jun; 92(11):1989-96. PubMed ID: 15928659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vinorelbine/docetaxel combination treatment of metastatic breast cancer: a phase I study.
    Bonneterre J; Campone M; Koralewski P; Blasinska-Morawiec M; Deporte-Fety R; Chatelut E; Leger F; Longerey B; Ecochard L; Douville I
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):365-73. PubMed ID: 17569044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
    Infante JR; Yardley DA; Burris HA; Greco FA; Farley CP; Webb C; Spigel DR; Hainsworth JD
    Clin Breast Cancer; 2009 Feb; 9(1):23-8. PubMed ID: 19299236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical phase II study of a non-anthracycline sequential combination of cisplatin-vinorelbine followed by docetaxel as first-line treatment in metastatic breast cancer.
    Shamseddine AI; Otrock ZK; Khalifeh MJ; Yassine HR; Charafeddine M; Abdel-Khalek Z; Chehal A; Bitar N; Jalloul R; Dheiny M; Dandashi A; Wehbeh M; El-Saghir NS
    Oncology; 2006; 70(5):330-8. PubMed ID: 17164589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
    Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
    Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines.
    Campone M; Dobrovolskaya N; Tjulandin S; Chen SC; Fourie S; Mefti F; Konstantinova M; Lefresne F; Meheust N; Jassem J
    Breast J; 2013; 19(3):240-9. PubMed ID: 23528159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study.
    Delva R; Pienkowski T; Tubiana N; Vanhoefer U; Longerey B; Douville I
    Cancer Chemother Pharmacol; 2007 May; 59(6):703-9. PubMed ID: 17021821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First line combination chemotherapy with docetaxel and vinorelbine in advanced breast cancer. A phase II study.
    Pectasides D; Dimopoulos MA; Aravantinos G; Kalophonos HP; Papacostas P; Briasoulis E; Cogas E; Papadimitriou C; Skarlos D; Kosmidis P; Fountzilas G
    Anticancer Res; 2001; 21(5):3575-80. PubMed ID: 11848526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
    Chan A; Conte PF; Petruzelka L; Tubiana-Mathieu N; Ganju V; Llombart A; Espie M; Majois F; Gil MG; Vaissiere N; Villanova G
    Anticancer Res; 2013 Jun; 33(6):2657-64. PubMed ID: 23749924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
    Lena MD; Ramlau R; Hansen O; Lorusso V; Wagner L; Barni S; Cristovao MM; Huber R; Alberola V; Mitrovic M; Colin C; Gasmi J
    Lung Cancer; 2005 Apr; 48(1):129-35. PubMed ID: 15777980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age.
    Addeo R; Faiola V; Guarrasi R; Montella L; Vincenzi B; Capasso E; Cennamo G; Rotundo MS; Tagliaferri P; Caraglia M; Del Prete S
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):285-92. PubMed ID: 17922275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of metastatic breast cancer with vinorelbine and docetaxel.
    Savio G; Laudani A; Leonardi V; Pepe A; Scianna C; Gebbia V; Agostara B
    Am J Clin Oncol; 2006 Jun; 29(3):276-80. PubMed ID: 16755181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly combination of docetaxel and vinorelbine in metastatic breast cancer: a phase I/II study.
    Cals L; Nouyrigat P; Valenza B; Pedinelli FJ; Juin P
    Oncology; 2004; 67(3-4):257-61. PubMed ID: 15557787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.
    De Maio E; Pacilio C; Gravina A; Morabito A; Di Rella F; Labonia V; Landi G; Nuzzo F; Rossi E; Silvestro P; Botti G; Di Bonito M; Curcio MP; Formichelli F; La Vecchia F; Staiano M; Maurea N; D'Aiuto G; D'Aiuto M; Thomas R; Signoriello G; Perrone F; de Matteis A
    BMC Cancer; 2007 Mar; 7():50. PubMed ID: 17374151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biweekly docetaxel and vinorelbine as first-line chemotherapy in metastatic breast cancer.
    Mayordomo JI; Milla A; Morales S; Yubero A; Lorenzo A; Baena JM; Modolell A; Sanz J; Illarramendi J; Garcia MJ; Machengs I; Burrilo MA; Tres A
    Clin Breast Cancer; 2004 Jun; 5(2):131-5. PubMed ID: 15245617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.
    Rugo HS; Stopeck AT; Joy AA; Chan S; Verma S; Lluch A; Liau KF; Kim S; Bycott P; Rosbrook B; Bair AH; Soulieres D
    J Clin Oncol; 2011 Jun; 29(18):2459-65. PubMed ID: 21555686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines.
    Vici P; Di Lauro L; Sergi D; Foggi P; Viola G; Mottolese M; Giotta F; Fattoruso SI; Corsetti S; Giannarelli D; Botti C; Lopez M
    Oncology; 2008; 75(3-4):175-81. PubMed ID: 18841031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.